S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New gold-backed currency could kill the Dollar (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
New gold-backed currency could kill the Dollar (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New gold-backed currency could kill the Dollar (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
New gold-backed currency could kill the Dollar (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New gold-backed currency could kill the Dollar (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
New gold-backed currency could kill the Dollar (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New gold-backed currency could kill the Dollar (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
New gold-backed currency could kill the Dollar (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
NASDAQ:MRTX

Mirati Therapeutics (MRTX) Stock Forecast, Price & News

$41.00
+4.50 (+12.33%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$36.53
$41.08
50-Day Range
$27.80
$41.00
52-Week Range
$27.30
$101.30
Volume
4.79 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.67

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
35.8% Upside
$55.67 Price Target
Short Interest
Bearish
16.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
0.55mentions of Mirati Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$33.70 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($11.85) to ($10.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

199th out of 962 stocks

Pharmaceutical Preparations Industry

78th out of 453 stocks


MRTX stock logo

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

MRTX Price History

MRTX Stock News Headlines

Mirati Therapeutics (NASDAQ:MRTX) Sees Strong Trading Volume
Mirati Therapeutics (NASDAQ:MRTX) Shares Gap Down to $34.05
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Massive Insider Trade At Mirati Therapeutics
Scotiabank Keeps Their Sell Rating on Mirati Therapeutics (MRTX)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Mirati Therapeutics CFO Laurie Stelzer Resigns
JMP Securities Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
3 Under-the-Radar Biotech Stocks to Buy in 2023
Piper Sandler Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
Mirati Therapeutics (MRTX) Has a New Rating from Barclays
Mirati Therapeutics Announces Proposed Public Offering
See More Headlines
Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRTX
Fax
N/A
Employees
587
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$55.67
High Stock Price Forecast
$83.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+35.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-740,870,000.00
Net Margins
-2,709.33%
Pretax Margin
-2,707.47%

Debt

Sales & Book Value

Annual Sales
$12.44 million
Book Value
$17.31 per share

Miscellaneous

Free Float
56,570,000
Market Cap
$2.40 billion
Optionable
Optionable
Beta
0.91

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Charles M. Baum M.D. (Age 65)
    Ph.D., Founder, Interim CEO, Pres, Head of R&D and Director
    Comp: $1.07M
  • Ms. Laurie D. Stelzer M.B.A. (Age 55)
    CFO & Principal Financial and Accounting Officer
    Comp: $609.06k
  • Dr. James G. Christensen Ph.D. (Age 55)
    Exec. VP & Chief Scientific Officer
    Comp: $1.76M
  • Dr. Alan Bart Sandler M.D. (Age 66)
    Exec. VP & Chief Medical Officer
    Comp: $591k
  • Mr. John B. Moriarty Jr. (Age 55)
    J.D., Chief Legal Officer
  • Mr. Michael E. Paolucci (Age 63)
    Chief People Officer
  • Mr. Benjamin J. Hickey M.B.A. (Age 48)
    Chief Commercial Officer
  • Dr. Kelly Covello Ph.D.
    VP & Head of Medical Affairs
  • Mr. Ryan Asay
    VP & Head of Corp. Affairs
  • Mr. Aaron Ondrey (Age 47)
    Sr. VP of Financial Planning & Analysis













MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MRTX shares.
View MRTX analyst ratings
or view top-rated stocks.

What is Mirati Therapeutics' stock price forecast for 2023?

12 Wall Street research analysts have issued twelve-month target prices for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $31.00 to $83.00. On average, they expect the company's stock price to reach $55.67 in the next year. This suggests a possible upside of 35.8% from the stock's current price.
View analysts price targets for MRTX
or view top-rated stocks among Wall Street analysts.

How have MRTX shares performed in 2023?

Mirati Therapeutics' stock was trading at $45.31 on January 1st, 2023. Since then, MRTX shares have decreased by 9.5% and is now trading at $41.00.
View the best growth stocks for 2023 here
.

When is Mirati Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our MRTX earnings forecast
.

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($3.04) earnings per share for the quarter, beating analysts' consensus estimates of ($3.23) by $0.19. The biotechnology company earned $13.70 million during the quarter, compared to analyst estimates of $13.17 million. Mirati Therapeutics had a negative net margin of 2,709.33% and a negative trailing twelve-month return on equity of 79.37%. The company's revenue was up 153.7% compared to the same quarter last year. During the same quarter last year, the business earned ($3.18) EPS.

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.66%), State Street Corp (4.41%), Camber Capital Management LP (3.07%), Rock Springs Capital Management LP (1.91%), Candriam S.C.A. (1.50%) and Assenagon Asset Management S.A. (1.39%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Faheem Hasnain, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends
.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $41.00.

How much money does Mirati Therapeutics make?

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.40 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.82) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

The company employs 587 workers across the globe.

Does Mirati Therapeutics have any subsidiaries?
The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -